Enzychem Lifesciences Corp
183490
Company Profile
Business description
Enzychem Lifesciences Corp develops and produces APIs and functional health foods. It manufactures veterinary medicine tablets, capsules, syrups, injections, ointments, solutions for the diagnosis and prevention of various diseases. The company is also developing drugs to treat chemotherapy-induced neutropenia, chemo-radiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, and others.
Contact
27 Gangnamdae-ro Seocho-gu
10th Floor, aT Center
Seoul135-280
KORT: +82 262137131
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
130
Stocks News & Analysis
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
stocks
Poor organic growth obscured by acquisition for ASX listed share
Sales dropped by 2% without impact of acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.20 | 15.00 | -0.17% |
| CAC 40 | 8,115.75 | 29.75 | 0.37% |
| DAX 40 | 24,888.56 | 281.79 | 1.15% |
| Dow JONES (US) | 50,579.70 | 294.04 | 0.58% |
| FTSE 100 | 10,466.26 | 22.79 | 0.22% |
| HKSE | 25,606.03 | 219.51 | 0.86% |
| NASDAQ | 26,343.97 | 50.87 | 0.19% |
| Nikkei 225 | 63,339.07 | 1,654.93 | 2.68% |
| NZX 50 Index | 12,991.31 | 113.24 | 0.88% |
| S&P 500 | 7,473.47 | 27.75 | 0.37% |
| S&P/ASX 200 | 8,657.00 | 15.10 | -0.17% |
| SSE Composite Index | 4,112.90 | 35.62 | 0.87% |